Azenta set to acquire B Medical SystemsAzenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for €410m. more ➔
Sartorius pays £415m for Albumedix LtdSartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs. more ➔
BioNtech SE expands collab with Genmab A/SAs Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base. more ➔
F2G to use $70m financing to advance olorofilmBritish antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm. more ➔
Sosei announces $1.2bn R&D collaboration with AbbvieSosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology. more ➔
UK-Spanish team to optimise efficacy of microbial production processesResearchers have presented a novel method to promote biofilm formation and thus to increase efficiency of biocatalysis in biotech production. more ➔
InflaRX set to file for MAA for vilobelimabInflaRx plans to apply for Emergency Use Authorization from the US FDA in Q3/2022 for vilobelimab, the company’s treatment for critically ill COVID-19 patients. more ➔
New Amsterdam Pharma merges with Frazier Lifesciences Acquisition Corp.Through a $325m SPAC transaction with Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Holding B.V. will go public on Nasdaq. The newly formed holding company, NewAmsterdam Pharma Company … more ➔
New antibody cocktail might fight all corona variantsA nasal antibody cocktail binding to the conserved S2 stalk region of SARS-COV-2 might end the corona pandemic. more ➔
French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) … more ➔
